← Back

Tianjin Lisheng Pharmaceutical Co Ltd

Tianjin Lisheng Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its portfolio includes pharmaceutical, traditional Chinese medicine, and antibiotic products in forms such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials, primarily for cardiovascular and digestive system applications. Named products include Shoubishan capsules, Jiayindapamide tablets, Sanyu Zhengtong tablets, Xifuni cefdinir dispersible tablets, and Youhao Maren soft capsules. The company also provides pharmaceutical manufacturing outsourcing and technology R&D services, and exports its products. Founded in 1951 and headquartered in Tianjin, China, it operates as a subsidiary of Tianjin Jinhao Pharmaceutical Co., Ltd.

Country
Price · split & dividend adjusted
News & notes moving 002393.CS
002393.CS▼

Lisheng Pharmaceutical's 2026 Interim Net Profit Falls 77.16% Year-on-Year

Lisheng Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 78.326 million yuan, down 77.16% from the same period last year. Total operating revenue was 642 million yuan, down 12.29% year-on-year. Net cash flow from operating activities was negative 44.1915 million yuan, down 163.28% year-on-year. The company's latest gross margin was 55.69%, up 0.38 percentage points from the previous quarter, marking two consecutive quarters of increase. Latest return on equity was 1.75%, down 5.11 percentage points from the same period last year. Diluted earnings per share were 0.25 yuan, down 77.48% year-on-year.
002393.CS ▼
Jiemian·28dRead more →
002393.CS2

Lisheng Pharmaceutical first-half revenue 642 million yuan, net profit attributable to parent 78.326 million yuan

Lisheng Pharmaceutical released its 2026 semi-annual report. In the first half, it achieved operating revenue of 642 million yuan, net profit attributable to the parent of 78.326 million yuan, and net profit excluding non-recurring gains and losses of 67.042 million yuan. The company said the year-on-year decline in net profit attributable to the parent was mainly due to the high base of non-recurring income such as large investment gains in the same period last year, while the core pharmaceutical main business maintained a stable operating trend. As of the end of June 2026, the company's asset-liability ratio was only 15.50 percent, with no interest-bearing debt pressure, and its comprehensive gross margin remained at 55.69 percent. Cumulative cash dividends since listing have reached 1.492 billion yuan. The company continues to advance consistency evaluation of generic drugs and the development of new product projects, strictly implements quality management across the full drug lifecycle, and ensures stable supply of classic products.
002393.CS
证券时报·28dRead more →
002393.CS▼2

Lisheng Pharmaceutical's first-half net profit plunges over 70 percent year on year

Lisheng Pharmaceutical released its 2026 interim report, showing first-half net profit attributable to shareholders of 78.33 million yuan, down 77.2 percent year on year. Operating revenue was 642 million yuan, down 12.3 percent. Net profit attributable to shareholders after deducting non-recurring items was 67.04 million yuan, down 35.7 percent. Net operating cash flow was negative 44.19 million yuan, down 163.3 percent. Second-quarter net profit attributable to shareholders was 26.44 million yuan, down 90.8 percent year on year. The company said volume-based procurement, consistency evaluation and other policy developments, as well as research and innovation risks and rising production factor costs, have brought multiple challenges to operations. Lisheng Pharmaceutical's share price has fallen 13 percent this year, closing at 15.10 yuan per share on August 20, with a market value of 4.655 billion yuan.
002393.CS ▼
读创财经·30dRead more →
© 2026 MarketDXAsset